Search

Filters
Types

Sign up for our free
equity research notes

Register
2706 Results for ‘Review’
Embed
QuotedData’s Investment Companies Annual Review – 2019

 In this issue The sector at the end of 2019 Performance data Performance by sector and fund Money in and out of the sector Money in and out of existing funds Money coming into existing funds Money going out of existing funds Liquidations, de-listings and trading cancellations Significant rating changes Major news stories Outlook for […]

LMS Capital reviewing management arrangements

LMS Capital reviewing management arrangements – LMS Capital has been reviewing its investment management arrangements since July. The review concluded with a majority of the board deciding that Gresham House Asset Management (“GHAM”) should continue as the appointed investment manager on terms that include both a reduction in the annual management fee (excluding any cash over […]

AIC sector review

AIC sector review To make it easier to compare similar funds, the Association of Investment companies (AIC) classifies its members into sector categories. To do this, it takes into account the aim and objective of the company and its investment policy. The idea is to allocate funds to sectors for the long-term and to avoid […]

Grading under review

Grading under review notices are issued by the Regulator for Social Housing on all Registered Providers than own 1,000 or more units. The following is an extract from a paper produced by the regulator. There are four governance grades: G1 The provider meets our governance requirements. G2 The provider meets our governance requirements but needs […]

Civitas Social Housing notes Bespoke Supportive Tenancies grading under review

Civitas Social Housing (CSH) has promptly announced that the Regulator of Social Housing (RSH) has issued a grading under review notice in respect of Bespoke Supportive Tenancies (BeST), one of the 15 housing associations that it is working with. CSH says that, as at 31 December 2018, BeST represents 4.3% of its net asset value […]

Civitas targeted by short-seller
QuotedData review of 2018 – Annual report investment companies

QuotedData review of 2018 – Annual report investment companies 2018 – the return of volatility A trade war, Brexit, US interest rate rises, slowing Chinese growth, a US government shutdown, a dispute over Italy’s budget, the Skripal poisonings, numerous elections – there was plenty to worry about in 2018. A last-minute dive left the US […]

QuotedData review of 2018 - Annual report investment companies
2018 new issue review

2018 new issue review – QuotedData’s James Carthew talks to Citywire’s Jen Hill about 2018’s clutch of new issues Investors were given an eclectic mix of opportunities within alternatives, in contrast to recent years when high-yielding propositions drove the vast majority of launches. The return of private equity and private equity like strategies – Augmentum […]

Another registered provider being reviewed by regulator

Another registered provider being reviewed by regulator – on 18 September 2018 the Regulator of Social Housing published a ‘Grading under review notice’ on Trinity Housing Association Limited. The notice says that “Trinity Housing Association Limited does not currently have a regulatory judgement as it previously held less than 1,000 homes. We are investigating a […]

Another registered provider being reviewed by regulator
SQN Secured Income Fund – strategic review “paying dividends”

SQN Secured Income Fund – strategic review “paying dividends” – The annual report for SQN Secured Income Fund (SSIF) for the 12 months to 30 June 2018 has been released. The NAV and share price of the company (on a total return per share basis) rose by +5.4% and fell by -0.5% respectively.  The foreign exchange exposure on non-Sterling assets (24.62% […]

FDA sets Feb target review date for IBT-backed Stemline Therapeutics

FDA sets Feb target review date for IBT-backed Stemline Therapeutics The US FDA has accepted  Stemline Therapeutics (Nasdaq:STML)’s filing for Elzonris (tagraxofusp) for review for blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare haematological cancer, and with priority review, the agency has set itself a PDUFA target action date of 21 February 2019 – although […]

FDA sets Feb target review date for IBT-backed Stemline Therapeutics